Perrigo Co. plc, with a diversified revenue stream, sells infant formulas for the store brand market, generic extended topical prescription (Rx) products and specialty pharmaceutical drugs. It's focusing on self-care products as part of its transformation into a self-care company from a healthcare company. The company divested its Rx segment to Altaris Capital Partners. The company completed its transformation to a consumer self-care company by reconfiguring the portfolio through the divestiture of RX business. Currently, the company has 2 reporting segments. Consumer Self Care Americas (CSCA): The segment comprises the U.S., Mexico and Canada CHC business, including OTC, contract manufacturing, infant formula and animal health categories. Consumer Self Care International?(CSCI): The segment comprises the branded consumer healthcare (BCH) segment mainly in Europe and the company's consumer-focused businesses in the UK and Australia. This segment includes UK liquids licensed products business.
| Revenue (Most Recent Fiscal Year) | $4.25B |
| Net Income (Most Recent Fiscal Year) | $-1.43B |
| PE Ratio (Current Year Earnings Estimate) | 5.85 |
| PE Ratio (Trailing 12 Months) | 5.13 |
| PEG Ratio (Long Term Growth Estimate) | 1.46 |
| Price to Sales Ratio (Trailing 12 Months) | 0.43 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.71 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 2.43 |
| Pre-Tax Margin (Trailing 12 Months) | -38.90% |
| Net Margin (Trailing 12 Months) | -41.85% |
| Return on Equity (Trailing 12 Months) | 11.25% |
| Return on Assets (Trailing 12 Months) | 4.08% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.32 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.32 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 1.31 |
| Inventory Turnover (Trailing 12 Months) | 2.43 |
| Book Value per Share (Most Recent Fiscal Quarter) | $18.13 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.50 |
| Earnings per Share (Most Recent Fiscal Year) | $2.75 |
| Diluted Earnings per Share (Trailing 12 Months) | $-12.51 |
| Exchange | NYSE |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Common Shares Outstanding | 138.77M |
| Free Float | 138.21M |
| Market Capitalization | $1.78B |
| Average Volume (Last 20 Days) | 3.02M |
| Beta (Past 60 Months) | 0.51 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 0.40% |
| Percentage Held By Institutions (Latest 13F Reports) | 95.91% |
| Annual Dividend (Based on Last Quarter) | $1.16 |
| Dividend Yield (Based on Last Quarter) | 9.04% |